BenQ Medical Technology (4116) — Cash Flow Reinvestment Rate

Latest as of June 2025: 0.42x

BenQ Medical Technology (4116) has a Cash Flow Reinvestment Rate of 0.42x as of June 2025, reinvesting NT$76.10 Million (capex NT$14.79 Million plus investments NT$-61.31 Million) from operating cash flow of NT$179.07 Million. See 4116 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.42x
(Capex + Investments) / Operating CF

Total Reinvested

NT$76.10 Million
Capex + Investments

Operating Cash Flow

NT$179.07 Million
TWD

Capital Expenditures

NT$14.79 Million
TWD

BenQ Medical Technology Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for BenQ Medical Technology across 8 annual periods. For the full cash flow conversion analysis, see how efficiently does BenQ Medical Technology generate cash.

Annual Cash Flow Reinvestment Rate for BenQ Medical Technology (2017–2024)

Year-by-year capital reinvestment analysis for BenQ Medical Technology. See BenQ Medical Technology (4116) flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2024 0.88x NT$195.80 Million NT$222.22 Million NT$175.48 Million ▲ +45.5%
2023 0.61x NT$267.96 Million NT$442.35 Million NT$139.28 Million ▲ +39.9%
2022 0.43x NT$164.04 Million NT$378.77 Million NT$60.05 Million ▼ -45.2%
2021 0.79x NT$95.91 Million NT$121.35 Million NT$32.92 Million ▲ +54.4%
2020 0.51x NT$77.53 Million NT$151.48 Million NT$42.37 Million ▲ +205.9%
2019 0.17x NT$28.32 Million NT$169.23 Million NT$21.15 Million ▼ -57.1%
2018 0.39x NT$49.21 Million NT$126.10 Million NT$31.36 Million ▼ -77.9%
2017 1.77x NT$128.91 Million NT$72.97 Million NT$112.31 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow